NIJMEGEN, Netherlands, July 11, 2024 /PRNewswire/ -- MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with Predica Diagnostics, a leading innovator in oncology diagnostics, to develop Predica's targeted RNA sequencing tests on the cost-effective MGI Next-generation sequencing platforms..

荷兰奈梅亨，2024年7月11日/PRNewswire/--MGI（MGI Tech Co.，Ltd.或其子公司，统称MGI）是一家致力于构建推动生命科学创新的核心工具和技术的公司，今天宣布与肿瘤学诊断领域的领先创新者Predica Diagnostics合作，在具有成本效益的MGI下一代测序平台上开发Predica的靶向RNA测序测试。。

The collaboration seeks to revolutionize molecular diagnostics by enabling early cancer detection and facilitating personalized targeted treatment strategies. By combining Predica Diagnostics' advanced sequencing assays with MGI's state-of-the-art Next-generation sequencing platforms, the initiative promises a rapid, accurate, and affordable solution for healthcare providers..

该合作旨在通过实现早期癌症检测和促进个性化靶向治疗策略来彻底改变分子诊断。通过将Predica Diagnostics的高级测序分析与MGI最先进的下一代测序平台相结合，该计划有望为医疗保健提供者提供快速，准确且价格合理的解决方案。。

Predica Diagnostics, renowned for its expertise in cervical cancer screening through its proprietary ciRNAseq-based test, CervicaDx, brings unparalleled precision in identifying high-risk HPV oncogenes and other (pre)malignancy biomarkers. By integrating this advanced diagnostic capability with MGI's robust and affordable DNBSEQ technology, the partnership aims to significantly enhance the accuracy and accessibility of diagnostic tests..

Predica Diagnostics凭借其专有的基于ciRNAseq的测试CervicaDx在宫颈癌筛查方面的专业知识而闻名，在识别高危HPV癌基因和其他（前）恶性生物标志物方面具有无与伦比的精确度。。。

Enhancing Affordability and Accessibility

提高可负担性和可及性

A core value of this partnership is making high-quality diagnostic and predictive testing more affordable and accessible. MGI Tech's DNBSEQ platforms, recognized for their cost-efficiency and scalability, will enable healthcare institutions to offer advanced genomic and transcriptomic testing at a lower cost.

这种伙伴关系的核心价值是使高质量的诊断和预测测试更加实惠和容易获得。MGI Tech的DNBSEQ平台以其成本效益和可扩展性而闻名，将使医疗机构能够以较低的成本提供先进的基因组和转录组测试。

Compared to existing NGS-based technologies, MGI's platform offers cost-effective and faster results. Within the collaboration, MGI's NGS platform will be deployed for conducting the final analysis of Predica's disruptive, ciRNAseq-based targeted RNA sequencing tests. This combination will help researchers and healthcare professionals to better predict patient prognosis and guide treatment with precision medicines..

与现有的基于NGS的技术相比，MGI的平台提供了经济高效且更快的结果。在合作中，MGI的NGS平台将被部署用于对Predica的破坏性，基于ciRNAseq的靶向RNA测序测试进行最终分析。这种组合将有助于研究人员和医疗保健专业人员更好地预测患者的预后，并指导精准药物的治疗。。

A Shared Vision for the Future

对未来的共同愿景

'Predica welcomes MGI as a partner with expertise that is highly synergistic with that of Predica', says Dr. William Leenders, CSO of Predica Diagnostics. 'Where our expertise lies in providing smart molecular diagnostic solutions for unmet medical needs, we see the combination with MGIs sequencing platforms as a perfect match for customers to get clinically important information on gene expression without the need for any on-site bio-informatic expertise.'.

Predica Diagnostics的CSO William Leenders博士说：“Predica欢迎MGI成为与Predica高度协同的专业合作伙伴。”我们的专业知识在于为未满足的医疗需求提供智能分子诊断解决方案，我们认为与MGIs测序平台的结合是客户获得基因表达临床重要信息的完美匹配，而无需任何现场生物信息学专业知识。”。

Dr. Yong Hou, General Manager of MGI Europe and Africa, adds, 'This partnership embodies our commitment to advancing healthcare through innovative genomic solutions. By combining our affordable and high-performance sequencing technology with Predica's expert diagnostic kits, we are poised to make a significant impact in the field of personalized medicine.'.

MGI Europe and Africa总经理侯勇博士补充道：“这种合作关系体现了我们通过创新的基因组解决方案推进医疗保健的承诺。通过将我们负担得起的高性能测序技术与Predica的专家诊断试剂盒相结合，我们将在个性化医疗领域产生重大影响。”。

MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries.

MGI科技有限公司（或其子公司，统称MGI）致力于构建推动生命科学创新的核心工具和技术。我们专注于生命科学和生物技术领域仪器、试剂和相关产品的研发、制造和销售。我们为精准医学、农业、医疗保健和各种其他行业提供实时、多组学和全方位的数字设备和系统。

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and has established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels.

MGI成立于2016年，现已成长为生命科学领域的领导者，为六大洲的客户提供服务，并在全球建立了研究、制造、培训和售后服务设施。MGI是少数能够独立开发和大规模生产临床级基因测序仪的公司之一，其吞吐量从Gb到Tb不等。

With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube..

凭借无与伦比的专业知识、尖端产品和对全球影响力的承诺，MGI继续塑造生命科学未来的发展轨迹。要了解更多信息，请访问https://en.mgi-tech.com/，LinkedIn，X和YouTube。。

Predica Diagnostics B.V is a spinoff from the Radboud UMC, active in the field of diagnostics, prognostics and prediction of treatment response in oncology. Predica Diagnostics aims to bring its ciRNAseq technology to patients in 1 to 2 years with a first focus on the CervicaDx test for improved cervical cancer screening.

Predica Diagnostics B.V是Radboud UMC的衍生产品，活跃于肿瘤学诊断，预后和治疗反应预测领域。Predica Diagnostics旨在在1至2年内将其ciRNAseq技术带给患者，首先关注宫颈癌筛查的宫颈癌检测。

The test allows non-invasive detection of cervical abnormalities with unprecedented specificity in women with a positive HPV test. Other tests in development concern tests to detect host-microbiome interactions and tests to detect activity of biological pathways and mutations that are amenable for targeted treatment with precision medicines, enabling the development of personalized treatment plans for cancer patients..

该测试可以无创检测HPV检测阳性的女性宫颈异常，具有前所未有的特异性。其他正在开发的测试涉及检测宿主-微生物组相互作用的测试，以及检测适合精准药物靶向治疗的生物途径和突变活性的测试，从而为癌症患者制定个性化治疗计划。。